CA2373252A1 - Long lasting anti-angiogenic peptides - Google Patents

Long lasting anti-angiogenic peptides Download PDF

Info

Publication number
CA2373252A1
CA2373252A1 CA002373252A CA2373252A CA2373252A1 CA 2373252 A1 CA2373252 A1 CA 2373252A1 CA 002373252 A CA002373252 A CA 002373252A CA 2373252 A CA2373252 A CA 2373252A CA 2373252 A1 CA2373252 A1 CA 2373252A1
Authority
CA
Canada
Prior art keywords
peptides
angiogenic
modified
conjugates
long lasting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002373252A
Other languages
French (fr)
Other versions
CA2373252C (en
Inventor
Dominique P. Bridon
Michele Rasamoelisolo
Karen Thibaudeau
Xicai Huang
Richard Beliveau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ConjuChem Biotechnologies Inc
Original Assignee
Conjuchem Inc.
Dominique P. Bridon
Michele Rasamoelisolo
Karen Thibaudeau
Xicai Huang
Richard Beliveau
Conjuchem Biotechnologies Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conjuchem Inc., Dominique P. Bridon, Michele Rasamoelisolo, Karen Thibaudeau, Xicai Huang, Richard Beliveau, Conjuchem Biotechnologies Inc. filed Critical Conjuchem Inc.
Publication of CA2373252A1 publication Critical patent/CA2373252A1/en
Application granted granted Critical
Publication of CA2373252C publication Critical patent/CA2373252C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)

Abstract

Modified anti-angiogenic peptides are disclosed. The modified peptides are capable of forming a peptidase stabilized anti-angiogenic peptide. The modified anti-angiogenic peptides, particularly modified kringle 5 peptides are capable of forming a conjugate with a blood protein. Conjugates are prepared from anti-angiogenic peptides, particularly kringle 5 peptides, by combining the peptide with a reactive functional group with a blood protein. The conjugates may be formed in vivo or ex vivo. The conjugates are administered to patients to provide an anti-angiogenic effect.
CA002373252A 1999-05-17 2000-05-17 Long lasting anti-angiogenic peptides Expired - Fee Related CA2373252C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13440699P 1999-05-17 1999-05-17
US60/134,406 1999-05-17
PCT/IB2000/000763 WO2000070665A2 (en) 1999-05-17 2000-05-17 Long lasting anti-angiogenic peptides

Publications (2)

Publication Number Publication Date
CA2373252A1 true CA2373252A1 (en) 2000-11-23
CA2373252C CA2373252C (en) 2007-08-07

Family

ID=22463240

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002373252A Expired - Fee Related CA2373252C (en) 1999-05-17 2000-05-17 Long lasting anti-angiogenic peptides

Country Status (9)

Country Link
EP (1) EP1171582A2 (en)
JP (3) JP4209086B2 (en)
CN (2) CN1698881A (en)
AU (1) AU764103B2 (en)
CA (1) CA2373252C (en)
SM (1) SM200000031B (en)
TW (1) TWI300414B (en)
WO (1) WO2000070665A2 (en)
ZA (2) ZA200106676B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002239414A1 (en) * 2000-11-02 2002-05-27 Bristol-Myers Squibb Company Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors
JP4280070B2 (en) 2001-02-16 2009-06-17 コンジュケム バイオテクノロジーズ インコーポレイテッド Long-lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders
ES2277173T3 (en) 2001-05-31 2007-07-01 Conjuchem Biotechnologies Inc. LONG-LIFE FUSION PEPTID INHIBITORS AGAINST HIV INFECTIONS.
AU2003246500A1 (en) * 2002-07-31 2004-02-16 Conjuchem Biotechnologies Inc. Long lasting natriuretic peptide derivatives
AP2203A (en) * 2002-09-24 2011-01-31 Frontier Biotechnologies Co Ltd Peptide derivative fusion inhibitors of HIV infection.
CN103897031A (en) * 2012-12-25 2014-07-02 深圳先进技术研究院 Chemically modified thymopentin and synthetic method thereof
CN104892725A (en) * 2015-05-19 2015-09-09 广州诺威生物技术有限公司 Novel naphthalene acetamide compound
CN109503700A (en) * 2017-09-14 2019-03-22 南京安吉生物科技有限公司 The blood vessel formation inhibitor IIM 3-1 of maleimide base group modification and its application
CN110372781B (en) * 2019-07-29 2021-11-16 深圳佳肽生物科技有限公司 Preparation method and application of Enfuvirtide

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0602290B1 (en) * 1992-12-04 1999-08-25 ConjuChem, Inc. Antibody-conjugated Hepatitis B surface antigen and use thereof
ATE262537T1 (en) * 1995-12-13 2004-04-15 Childrens Medical Center ENDOTHELAR CELL PROLIFERATION INHIBITOR AND USE THEREOF
HU224827B1 (en) * 1996-05-03 2006-02-28 Abbott Lab Novel antiangiogenic peptides polynucleotides encoding same and methods for inhibiting angiogenesis
EP2033661A1 (en) * 1997-11-07 2009-03-11 ConjuChem Biotechnologies Inc. Methods of screening affinity marker libraries
DE69804974T2 (en) * 1997-11-07 2002-11-07 Conjuchem Inc OPIOID CONJUGATES WITH ENDOGENIC CARRIER PROTEINS
IL133053A0 (en) * 1998-03-23 2001-03-19 Conjuchem Inc Local delivery of long lasting therapeutic agents
GB9815505D0 (en) * 1998-07-16 1998-09-16 Adprotech Plc Polypeptide derivatives

Also Published As

Publication number Publication date
ZA200106676B (en) 2002-07-19
JP4209086B2 (en) 2009-01-14
JP2003500341A (en) 2003-01-07
TWI300414B (en) 2008-09-01
ZA200109110B (en) 2002-06-13
CN1698881A (en) 2005-11-23
CN101289500A (en) 2008-10-22
SM200000031A (en) 2001-11-21
AU4774800A (en) 2000-12-05
WO2000070665A3 (en) 2001-04-19
TW200524957A (en) 2005-08-01
AU764103B2 (en) 2003-08-07
EP1171582A2 (en) 2002-01-16
JP2009143941A (en) 2009-07-02
CA2373252C (en) 2007-08-07
WO2000070665A2 (en) 2000-11-23
SM200000031B (en) 2001-11-21
JP2008110986A (en) 2008-05-15

Similar Documents

Publication Publication Date Title
SI1180121T1 (en) Long lasting insulinotropic peptides
WO2005081711A3 (en) Monomethylvaline compounds capable of conjugation to ligands
WO2006081249A8 (en) Conjugates of biologically active proteins having a modified in vivo half-life
WO2005097202A3 (en) Use of serum albumin binding peptides conjugates for the preparation of a medicament
EP2112161A3 (en) Peptides that lower blood glucose levels
WO2000066175A3 (en) Conjugates as therapies for cancer and prostate diseases
CA2373680A1 (en) Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
WO2001058472A3 (en) Botulinum toxin pharmaceutical compositions
HUP0300133A2 (en) Amphiphilic polymers and polypeptide conjugates comprising same
AU2002229510A1 (en) Combined use of factor vii polypeptides and factor viii polypeptides
WO1999048536A3 (en) Delivery of long lasting therapeutic agents by forming covalent attachments in vivo
WO2006050930A3 (en) Conjugates with enhanced cell uptake activity
EP1790728A3 (en) Imaging, diagnosis and treatment of disease
CA2373252A1 (en) Long lasting anti-angiogenic peptides
WO2003037272A3 (en) Thymosin alpha 1 peptide/polymer conjugates
AU2002309122A1 (en) Compositions based on branched chain amino acids for improving the myocardial ventricular function in patients suffering from diabetes
WO2001036656A3 (en) A complex between hyaluronic acid and a biomolecule and its use
WO2000058466A3 (en) Protease resistant flint analogs
WO2001068676A3 (en) Lhrh-antagonists, production and use thereof as medicament
WO2004029075A3 (en) Peptide nucleic acids having improved uptake and tissue distribution
WO2002012336A3 (en) TGF-β THERAPEUTICS, COMPOSITIONS AND METHODS OF USE
WO2001042423A3 (en) Compositions and methods for detecting stress-inducible proteins
TNSN00190A1 (en) ANTI-ANGIOGENIC PEPTIDES WITH LONG-TERM ACTION
WO2001035937A3 (en) Lipid complex of alkycyclines

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20130517